RBC Capital Markets initiated coverage on IQVIA Holdings Inc. IQV, noting the company's biggest differentiator is its data assets. The analyst says IQVIA is the largest global contract research organization.
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
IQVIA Holdings Inc. stock is up following Q2 earnings, following business upsides across its portfolio. Q2 earnings showed strong performance in TAS and R&DS divisions, with a record backlog and increased guidance for FY'24. Implied valuations are corroborated at a $260/share price objective, with potential further technical upside to $283/share if momentum sustains.
IQVIA (IQV) rides high on robust segmental performance, boosting the company's top line. However, elevated operating expenses and weak liquidity are a major concern.
Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Investors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Waters (WAT). But which of these two companies is the best option for those looking for undervalued stocks?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IQVIA Holdings Inc IQV posted better-than-expected second-quarter earnings on Monday.
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.
IQVIA's (IQV) second-quarter 2024 earnings and revenues increase year over year.
IQVIA Holdings Inc IQV reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.